Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis.

British journal of haematology - 1 Jan 2010

Ruano Irene, Gargini Ricardo, Izquierdo Marta

Abstract excerpt

Gain-of-function mutations of kit tyrosine kinase receptor are associated with mastocytosis. Two subclones of the HMC1 mast leukaemia cell line were used; both express an identical KIT allele-specific regulatory type mutation (V560G), but differ in that one also expresses an enzymatic site type m...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Tocopherol
Share to Combined Modality Therapy
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Mastocytosis

Share to Neoplasm Transplantation

Share to Proto-Oncogene Proteins c-kit

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 19804454
DOI: 10.1111/j.1365-2141.2009.07918.x

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19804454-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis.PMID 19804454Read ↗

Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.Semantic proximity Read ↗

CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.Semantic proximity Read ↗

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.Semantic proximity Read ↗

Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disordersSemantic proximity Read ↗

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfectionSemantic proximity Read ↗

AXL mediates mast cell survival and resistance to tyrosine kinase inhibitors in mastocytosisSemantic proximity Read ↗

Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.Semantic proximity Read ↗

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.Semantic proximity Read ↗

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.Semantic proximity Read ↗

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.Semantic proximity Read ↗

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Semantic proximity Read ↗

Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.